Linked Life Data

18484593

Source:http://linkedlifedata.com/resource/pubmed/id/18484593

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2008-6-30
pubmed:abstractText
Patients with recurrent or metastatic HNC have a poor response and survival with currently available chemotherapy agents. Thus, new agents are needed. The authors report the results of a phase II trial of irinotecan and cisplatin in patients with metastatic or recurrent HNC.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0008-543X
pubmed:author
pubmed:copyrightInfo
(Copyright) 2008 American Cancer Society.
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
113
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
186-92
pubmed:meshHeading
pubmed:year
2008
pubmed:articleTitle
Phase II trial of irinotecan plus cisplatin in patients with recurrent or metastatic squamous carcinoma of the head and neck.
pubmed:affiliation
Division of Hematology and Oncology, Department of Medicine, Vanderbilt University School of Medicine, 2220 Pierce Avenue, 777 PRB, Nashville, TN 37232, USA. jill.gilbert@vanderbilt.edu
pubmed:publicationType
Journal Article, Clinical Trial, Phase II